0001079973-24-001323.txt : 20240826 0001079973-24-001323.hdr.sgml : 20240826 20240826060109 ACCESSION NUMBER: 0001079973-24-001323 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20240823 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240826 DATE AS OF CHANGE: 20240826 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Scorpius Holdings, Inc. CENTRAL INDEX KEY: 0001476963 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 262844103 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35994 FILM NUMBER: 241237688 BUSINESS ADDRESS: STREET 1: 627 DAVIS DRIVE STREET 2: SUITE 300 CITY: MORRISVILLE STATE: NC ZIP: 27560 BUSINESS PHONE: 919-240-7133 MAIL ADDRESS: STREET 1: 627 DAVIS DRIVE STREET 2: SUITE 300 CITY: MORRISVILLE STATE: NC ZIP: 27560 FORMER COMPANY: FORMER CONFORMED NAME: NightHawk Biosciences, Inc. DATE OF NAME CHANGE: 20220502 FORMER COMPANY: FORMER CONFORMED NAME: HEAT BIOLOGICS, INC. DATE OF NAME CHANGE: 20091117 8-K 1 scpx_8k.htm FORM 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): August 23, 2024

Scorpius Holdings, Inc.

(Exact name of registrant as specified in charter)

Delaware

(State or other jurisdiction of incorporation)

001-35994	26-2844103
(Commission File Number)	(IRS Employer Identification No.)

627 Davis Drive, Suite 300

Morrisville, North Carolina 27560

(Address of principal executive offices and zip code)

(919) 240-7133

(Registrant’s telephone number including area code)

(Former Name and Former Address)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:

¨

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨

Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12)

¨

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.0002 par value per share	SCPX	NYSE American LLC
Common Stock Purchase Rights	None	NYSE American LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 1.01 Entry into a Material Definitive Agreement.

On August 23, 2024, Scorpius Holdings, Inc. (the “Company”) entered into amendments to Jeff Wolf’s and William Ostrander’s employment agreements to provide for an incentive performance bonus to align senior executive compensation with our growth objectives on meeting sales targets and booking goals.

The agreement that the Company had entered into Jeffrey Wolf, dated January 4, 2021, as amended December 7, 2022, was amended on August 23, 2024 (the “Wolf Amendment”) to provide for the payment to him of a special performance bonus equal to: (i) 5% of the contract values of New Bookings (as defined below) through the first $6 million of New Bookings prior to December 31, 2024; and (ii) 2.5% of the contract values of New Bookings of $6 million or more prior to December 31, 2024.

The agreement that the Company had entered into with William Ostrander, dated January 1, 2022, as amended December 7, 2022 and December 11, 2022, was amended on August 23, 2024 (the “Ostrander Amendment”) to provide for the payment to him of a special performance bonus equal to: (i) 2.5% of the contract values of New Bookings (as defined below) through the first $6 million of New Bookings prior to December 31, 2024; and (ii) 1.25% of the contract values of New Bookings of $6 million or more prior to December 31, 2024.

New Bookings is defined as the Company’s execution of definitive agreements with customers for the provision of new services on or after the date of the amended employment agreements and prior to December 31, 2024.

The foregoing description of the terms of the Wolf Amendment and Ostrander Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of such documents, copies of which are filed as Exhibit 10.1 and 10.2, respectively, to this Current Report on Form 8-K and incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
10.1		Amendment No. 2 to Jeffrey Wolf Employment Agreement with the Company dated as of August 23, 2024
10.2		Amendment No. 3 to William Ostrander Employment Agreement with the Company dated as of August 23, 2024
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: August 26, 2024	SCORPIUS HOLDINGS, INC.


	By:	/s/ Jeffrey Wolf
	Name:	Jeffrey Wolf
	Title:	Chairman, President and Chief Executive Officer

EX-10.1 2 ex10x1.htm AMENDMENT NO. 3 TO EMPLOYMENT AGREEMENT - JEFFREY WOLF

Exhibit 10.1

AMENDMENT NO. 3 TO EMPLOYMENT AGREEMENT

This Amendment No. 3 (this “Amendment”) effective as of August 23, 2024 to the Employment Agreement, dated January 1, 2022, as amended December 7, 2022 and December 11, 2023 (the “Employment Agreement”), by and between Scorpius Holdings, Inc. (the “Corporation”) and William Ostrander (“Executive”). Capitalized terms used herein without definition shall have the meanings assigned in the Employment Agreement.

WHEREAS, Executive was retained under the Employment Agreement by the Corporation to serve as its Chief Financial Officer and Corporate Secretary; and

WHEREAS, the Board has determined to pay a performance bonus to the executive officers of the Corporation as an incentive to increase new 2024 client bookings.

NOW THEREFORE, for the mutual promises contained herein and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereto agree to amend the Employment Agreement as follows:

1. Amendment. Section 3 of the Employment Agreement is hereby amended by the addition of the following new section (d):

“(d) 2024 SPECIAL PERFORMANCE BONUS. The Company agrees to pay the Executive a bonus equal to: (i) 2.5% of the contract values of New Bookings through the first $6 million of New Bookings; and (ii) 1.25% of the contract values of New Bookings of $6 million or more. New Bookings shall be defined as the Corporation’s execution of definitive agreements with customers for the provision of new services on or after the date of this Amendment and prior to December 31, 2024.”

2. Severability. The provisions of this Amendment are severable and if any part or it is found to be unenforceable the other paragraphs shall remain fully valid and enforceable.

3. No Other Amendments; Confirmation. All other terms of the Agreement shall remain in full force and effect. The Agreement, as amended by this Amendment, constitutes the entire agreement between the parties with respect to the subject matter thereof.

4. Counterparts. This Amendment may be executed in one or more counterparts, each of which shall be deemed an original but both of which together shall constitute one and the same instrument.

5. Governing Law. This Amendment is made and shall be construed and performed under the laws of the State of North Carolina without regard to its choice or conflict of law principles and the parties agree to North Carolina as the exclusive venue for any disputes arising hereunder.

[Signature Page Follows]

IN WITNESS WHEREOF, the parties hereto have caused this Amendment No. 3 to the Employment Agreement to be duly executed as of the day and year first above written.


	SCORPIUS HOLDINGS, INC.

	By:	/s/ Jeffrey Wolf
	Name:	Jeffrey Wolf
	Title:	Chief Executive Officer

	/s/ William Ostrander
	William Ostrander

EX-10.2 3 ex10x2.htm AMENDMENT NO. 2 TO EMPLOYMENT AGREEMENT - WILLIAM OSTRANDER

Exhibit 10.2

AMENDMENT NO. 2 TO EMPLOYMENT AGREEMENT

This Amendment No. 2 (this “Amendment”) effective as of August 23, 2024 to the Employment Agreement, dated January 4, 2021, as amended December 7, 2022 (the “Employment Agreement”), by and between Scorpius Holdings, Inc. (the “Corporation”) and Jeffrey Wolf (“Executive”). Capitalized terms used herein without definition shall have the meanings assigned in the Employment Agreement.

WHEREAS, Executive was retained under the Employment Agreement by the Corporation to serve as its President and Chief Executive Officer; and

WHEREAS, the Board has determined to pay a performance bonus to the executive officers of the Corporation as an incentive to increase new 2024 client bookings.

NOW THEREFORE, for the mutual promises contained herein and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereto agree to amend the Employment Agreement as follows:

1. Amendment. Section 5 of the Employment Agreement is hereby amended by the addition of the following new section (c):

“(c) 2024 SPECIAL PERFORMANCE BONUS. The Company agrees to pay the Executive a bonus equal to: (i) 5% of the contract values of New Bookings through the first $6 million of New Bookings; and (ii) 2.5% of the contract values of New Bookings of $6 million or more. New Bookings shall be defined as the Corporation’s execution of definitive agreements with customers for the provision of new services on or after the date of this Amendment and prior to December 31, 2024.

2. Severability. The provisions of this Amendment are severable and if any part or it is found to be unenforceable the other paragraphs shall remain fully valid and enforceable.

3. No Other Amendments; Confirmation. All other terms of the Agreement shall remain in full force and effect. The Agreement, as amended by this Amendment, constitutes the entire agreement between the parties with respect to the subject matter thereof.

4. Counterparts. This Amendment may be executed in one or more counterparts, each of which shall be deemed an original but both of which together shall constitute one and the same instrument.

5. Governing Law. This Amendment is made and shall be construed and performed under the laws of the State of North Carolina without regard to its choice or conflict of law principles and the parties agree to North Carolina as the exclusive venue for any disputes arising hereunder.

[Signature Page Follows]

IN WITNESS WHEREOF, the parties hereto have caused this Amendment No. 2 to the Employment Agreement to be duly executed as of the day and year first above written.


	SCORPIUS HOLDINGS, INC.

	By:	/s/ William Ostrander
	Name:	William Ostrander
	Title:	Chief Financial Officer

	/s/ Jeffrey Wolf
	Jeffrey Wolf

EX-101.SCH 4 scpx-20240823.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 5 scpx-20240823_def.xml XBRL DEFINITION FILE EX-101.LAB 6 scpx-20240823_lab.xml XBRL LABEL FILE Class of Stock [Axis] Common Stock [Member] Common Stock Purchase Rights [Member] Statement [Table] Statement [Line Items] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Common Stock No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 7 scpx-20240823_pre.xml XBRL PRESENTATION FILE XML 9 R1.htm IDEA: XBRL DOCUMENT

Cover	Aug. 23, 2024
Document Type	8-K
Amendment Flag	false
Document Period End Date	Aug. 23, 2024
Entity File Number	001-35994
Entity Registrant Name	Scorpius Holdings, Inc.
Entity Central Index Key	0001476963
Entity Tax Identification Number	26-2844103
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	627 Davis Drive
Entity Address, Address Line Two	Suite 300
Entity Address, City or Town	Morrisville
Entity Address, State or Province	NC
Entity Address, Postal Zip Code	27560
City Area Code	919
Local Phone Number	240-7133
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Entity Emerging Growth Company	false
Common Stock [Member]
Common Stock	Common Stock, $0.0002 par value per share
Trading Symbol	SCPX
Security Exchange Name	NYSEAMER
Common Stock Purchase Rights [Member]
Common Stock	Common Stock Purchase Rights
Trading Symbol	None
Security Exchange Name	NYSEAMER

EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.2.u1 html 3 23 1 false 2 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://scorpiusbiologics.com/role/Cover Cover Cover 1 false false All Reports Book All Reports scpx-20240823.xsd scpx-20240823_def.xml scpx-20240823_lab.xml scpx-20240823_pre.xml scpx_8k.htm http://xbrl.sec.gov/dei/2024 true false JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "scpx_8k.htm": { "nsprefix": "SCPX", "nsuri": "http://scorpiusbiologics.com/20240823", "dts": { "schema": { "local": [ "scpx-20240823.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" ] }, "definitionLink": { "local": [ "scpx-20240823_def.xml" ] }, "labelLink": { "local": [ "scpx-20240823_lab.xml" ] }, "presentationLink": { "local": [ "scpx-20240823_pre.xml" ] }, "inline": { "local": [ "scpx_8k.htm" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 1, "axisCustom": 0, "memberStandard": 1, "memberCustom": 1, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2024": 2 }, "contextCount": 3, "entityCount": 1, "segmentCount": 2, "elementCount": 65, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2024": 26 }, "report": { "R1": { "role": "http://scorpiusbiologics.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-08-23", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "scpx_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-08-23", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "scpx_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentDescription", "presentation": [ "http://scorpiusbiologics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://scorpiusbiologics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AnnualInformationForm", "presentation": [ "http://scorpiusbiologics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://scorpiusbiologics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://scorpiusbiologics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockDomain", "presentation": [ "http://scorpiusbiologics.com/role/Cover" ], "auth_ref": [] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": [ "http://scorpiusbiologics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Common Stock [Member]" } } }, "auth_ref": [] }, "SCPX_CommonStockPurchaseRightsMember": { "xbrltype": "domainItemType", "nsuri": "http://scorpiusbiologics.com/20240823", "localname": "CommonStockPurchaseRightsMember", "presentation": [ "http://scorpiusbiologics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Common Stock Purchase Rights [Member]" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CountryRegion", "presentation": [ "http://scorpiusbiologics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://scorpiusbiologics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAccountingStandard", "presentation": [ "http://scorpiusbiologics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAnnualReport", "presentation": [ "http://scorpiusbiologics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://scorpiusbiologics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://scorpiusbiologics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://scorpiusbiologics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodStartDate", "presentation": [ "http://scorpiusbiologics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": [ "http://scorpiusbiologics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentRegistrationStatement", "presentation": [ "http://scorpiusbiologics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://scorpiusbiologics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyReport", "presentation": [ "http://scorpiusbiologics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": [ "http://scorpiusbiologics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://scorpiusbiologics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://scorpiusbiologics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://scorpiusbiologics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": [ "http://scorpiusbiologics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine3", "presentation": [ "http://scorpiusbiologics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://scorpiusbiologics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCountry", "presentation": [ "http://scorpiusbiologics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://scorpiusbiologics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://scorpiusbiologics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://scorpiusbiologics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://scorpiusbiologics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://scorpiusbiologics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://scorpiusbiologics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://scorpiusbiologics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityExTransitionPeriod", "presentation": [ "http://scorpiusbiologics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://scorpiusbiologics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": [ "http://scorpiusbiologics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://scorpiusbiologics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://scorpiusbiologics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPrimarySicNumber", "presentation": [ "http://scorpiusbiologics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://scorpiusbiologics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://scorpiusbiologics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": [ "http://scorpiusbiologics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": [ "http://scorpiusbiologics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://scorpiusbiologics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityVoluntaryFilers", "presentation": [ "http://scorpiusbiologics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://scorpiusbiologics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Extension", "presentation": [ "http://scorpiusbiologics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://scorpiusbiologics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NoTradingSymbolFlag", "presentation": [ "http://scorpiusbiologics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://scorpiusbiologics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://scorpiusbiologics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementTenderOffer", "presentation": [ "http://scorpiusbiologics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://scorpiusbiologics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Common Stock", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12gTitle", "presentation": [ "http://scorpiusbiologics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://scorpiusbiologics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityReportingObligation", "presentation": [ "http://scorpiusbiologics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SolicitingMaterial", "presentation": [ "http://scorpiusbiologics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementClassOfStockAxis", "presentation": [ "http://scorpiusbiologics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]" } } }, "auth_ref": [] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": [ "http://scorpiusbiologics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Statement [Line Items]" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": [ "http://scorpiusbiologics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Statement [Table]" } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://scorpiusbiologics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "WrittenCommunications", "presentation": [ "http://scorpiusbiologics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14a", "Subsection": "12" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 17 0001079973-24-001323-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001079973-24-001323-xbrl.zip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end XML 18 scpx_8k_htm.xml IDEA: XBRL DOCUMENT 0001476963 2024-08-23 2024-08-23 0001476963 us-gaap:CommonStockMember 2024-08-23 2024-08-23 0001476963 SCPX:CommonStockPurchaseRightsMember 2024-08-23 2024-08-23 iso4217:USD shares iso4217:USD shares false 0001476963 8-K 2024-08-23 Scorpius Holdings, Inc. DE 001-35994 26-2844103 627 Davis Drive Suite 300 Morrisville NC 27560 919 240-7133 false false false false Common Stock, $0.0002 par value per share SCPX NYSEAMER Common Stock Purchase Rights None NYSEAMER false